STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Roshni Bibi, Melvin George, Koustav Sarkar
Format: Artículo Open Access
Published: Wiley 2026
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867018767211429888
author Roshni Bibi
Melvin George
Koustav Sarkar
author_facet Roshni Bibi
Melvin George
Koustav Sarkar
Roshni Bibi
Melvin George
Koustav Sarkar
collection Wiley Open Access
contents STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC ) Roshni Bibi Melvin George Koustav Sarkar Immunology ABSTRACT Non‐small cell lung cancer (NSCLC) is an aggressive malignancy necessitating innovative therapeutic approaches to augment antitumour immunity. Our study examined the function of the STAT2 protein in CD4 + T helper cells, which are essential for the immune response to cancer. We utilised CRISPR/Cas9 to ablate STAT2 in CD4 + T cells from stage I NSCLC patients ( n  = 30), assessing its impact on cellular function and diverse epigenetic pathways. Our findings indicate that the depletion of STAT2 markedly enhances the anti‐cancer efficacy of T lymphocytes. Deletion of STAT2 diminished oxidative stress, enhanced the synthesis of advantageous TH1 cytokines. STAT2 depletion reduced DNA methylation and R‐loop formation. T cells deficient in STAT2 showed enhanced efficacy in activating cytotoxic T lymphocytes to eliminate cancer cells. These findings identify STAT2 as a crucial regulator of immune function in the lung cancer microenvironment. Targeted STAT2 inhibition in tumour‐reactive T cells may reinstate anti‐tumour immunity, although systemic inhibition requires further research on targeted intervention strategies. 10.1111/imm.70121 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1111/imm.70121
format Artículo Open Access
id wiley_oa_10_1111_imm_70121
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )
Roshni Bibi
Melvin George
Koustav Sarkar
Immunology
STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC ) Roshni Bibi Melvin George Koustav Sarkar Immunology ABSTRACT Non‐small cell lung cancer (NSCLC) is an aggressive malignancy necessitating innovative therapeutic approaches to augment antitumour immunity. Our study examined the function of the STAT2 protein in CD4 + T helper cells, which are essential for the immune response to cancer. We utilised CRISPR/Cas9 to ablate STAT2 in CD4 + T cells from stage I NSCLC patients ( n  = 30), assessing its impact on cellular function and diverse epigenetic pathways. Our findings indicate that the depletion of STAT2 markedly enhances the anti‐cancer efficacy of T lymphocytes. Deletion of STAT2 diminished oxidative stress, enhanced the synthesis of advantageous TH1 cytokines. STAT2 depletion reduced DNA methylation and R‐loop formation. T cells deficient in STAT2 showed enhanced efficacy in activating cytotoxic T lymphocytes to eliminate cancer cells. These findings identify STAT2 as a crucial regulator of immune function in the lung cancer microenvironment. Targeted STAT2 inhibition in tumour‐reactive T cells may reinstate anti‐tumour immunity, although systemic inhibition requires further research on targeted intervention strategies. 10.1111/imm.70121 http://onlinelibrary.wiley.com/termsAndConditions#vor
title STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )
topic Immunology
url https://onlinelibrary.wiley.com/doi/10.1111/imm.70121